Home » Newsletters » BioWorld Science

BioWorld Science

June 13, 2014

View Archived Issues

Phase II results on cediranib in advanced biliary tract cancer

Researchers identify novel polymorphism associated with the risk of miscarriage

Synthetic Biologics and Enterome Bioscience collaborate on microbiome research

FDA grants orphan drug status to Afinitor in DLBCL

Edison Pharmaceuticals obtains FDA orphan drug designation for Leigh syndrome candidate

Isis Pharmaceuticals earns milestone payment for start of phase I ISIS-AR-Rx study

BrainStorm Cell Therapeutics initiates preclinical studies of stem cell therapy in autism

Nymox Pharmaceutical reports new safety study data for NX-1207

Lilly reports topline results from phase III trial of ramucirumab

Amgen presents first-in-human results for AMG-780

High-affinity SV2A PET tracer [11C]UCB-J shows promise in animal models

VGX-100 shows promise as monotherapy or as combination with bevacizumab in first-in-human trial

X-Chem and Pfizer form multi-target collaboration

Beactica enters into drug discovery collaboration with Medivir

AstraZeneca inlicenses Synairgen's SNG-001

University of Pennsylvania researchers gain access to SomaLogic's SOMAscan proteomics platform

Tipelukast shows promise in pulmonary fibrosis model

Genomic Health reports topline results from independent validation study

Chinese company reports discovery of H+/K+-ATPase inhibitors

U.S. investigators patent new compounds for diabetes and obesity

Adelaide Research and Innovation synthesizes novel calpain inhibitors

Northwest Biotherapeutics reports data from phase I/II trial of DCVax-Direct

IRM and Novartis report synthesis of compounds for malaria

Bayer patents detail novel CDK9/CycT1 inhibitors

Phase III data: efficacy of fluticasone furoate/vilanterol improved by adding umeclidinium in COPD

Ruthigen to begin human trials of RUT-58-60 in the U.S.

FDA approves Gadavist as a contrast agent for the evaluation of breast cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 8, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 8, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...